Human pappilomavirus genotype in cervical tissue of patients

with Cervical Intraepithelial Neoplasia (CIN) 1, CIN 2, and CIN 3 by Mastutik, Gondo et al.
plssN 0854-038r
Vol. 24 No. 3 September - December 20 l6
Articles
o Human pappilomavirus tenorype in cervical rissue of
patients with Cervical lntraepithelial Neoplasia (ClN) l,
CIN 2. and CIN 3
O Parity as failure determinans of labor induction in
Bangka Belitung
O The comparison of creadnine and cystatin C value in
preeclampsia severiry and neonatal outcome
O Therapeutic effectiveness of rat bone marrow stem cells
in Poly Cystic Ovary Syndrome Mice Model on
folliculogenesis,TGF-9, GDF-9 expression, and
estrogen,TNF-ft and androgen levels
o lnfluence of prenatal class to the practice of p4K(Birth Planning and Prevention of Birth
Complication)
o Three years survival rate of epithelial ovarian cancer
pariens in Dr. Kariadi Hospital, Semarang, Central
Java
o Characterisdcs overview of mother with perinatal
death at Dr. Soeromo Hospital in 201 5
Cervical lntraepithelial Neoplasia (ClN) 2 with
hematoxylin eosin staining
published by
Department of Obstetrics & Gynecology, Airlangga University
ln Collaboration with lndonesian Society oi'Obstetr[, & Cyne.otogy
Accredited by Ministry of Education and Culture. Republic of lndonesia.
No. 58/DtKTt/Kep/20t3
Vol. 24 No.3 September December 2016 pISSN 0854-038 I
Olaletuie
ACCREDITED
Direcrorate General of Higher Education,
Ministry of Education and Culture, Republic of lndonesia
No. 58/DlKTt/Kep/20 t 3
EDITORIAL BOARD
Editor-in-Chief
Dr. Hendy Hendano, dr, SpOG(K)
Vice Editor-in-Chief
M. Aldika Akbar, dr, SpOG(K)
Editor-in-Chief Emeritus
Prof. Soehartono Ds, dr, SpOG(K)
pror. Dr. Erry Gumita. o".n,"., o.Irffi3'&5,Tj.tilt-""." ,., ,"ewono. dr. sDoG.KrBakono Winardi, dr. S1p9(!. Hari paraton, di, SpOC1f1, O.. eoe'a;o nanono, il,irddfflDr. Brahmana Askandar T1, dr. SpOG(K), Budt pnsetyo, di. SpOC1f1, Lh"n S","ji, a,., ipailffSri Ratna Dwinintsih, dr:.SqOG([), EiShry Mardipn Kurniawaci, dr, SpOG(K), Dr. Ema*",i, jr, SpbClflpungky Mulawardhana, dr, SpOG, My Ardianta Widyanugot", a., ipOC-' - ' -.- -
Fertirity and Reprooro,:".I"fl_,.:llllq 
l.=.tr."#il&tilr1rm-ao dr,,spoG(K) (Universitas sam Ratutansi)Shofwat Widad, dr, SpOG(K) (Universitas 6adjah Mada), ri.. if".i.r ft"rnr Uia"n,.,ji li. ll"allp<iL(rl(universitas Diponesoro), Dr. r waFn Arsana Wi;asa, ar, spocrrj itj"*rsitas Brawijaya), AiAN Anantasiia, dr, spoc(K)(universitas udaFna)' Prof Dr- Nusratuddin Abdullah, a.. spoitiiiulllrsitas Hasanuddinj, ir"r. o.. !ri, s"^,".", dr, spoG(K)(universi6s AirtanSga), prof. sams,rhadi,.d1,.:?9c(K) rudr*il. iiil"g8"i, r.to.,,"tu.,,.t,'i..r. o.. !6-", l'i"se, dr, SpoG(K)(universitas Padia,aran), Prof Dr' Freddy W Wagey, jr, spoc 1r1 lunivTrlitas sam RatulanSi), o.. rr.i..."" x-"."n, dr, spoc(K)(Universitas Brawijara), Tiok GA s!*"ra-".i". a., lpoci( iurr#g_u9"rya or. sri suristvowati, dr, spoc(K)(Universitas Neceri.Sebetas_MareQ, Or. Fery y;s;izal, dr, apOG(Kj, M.Kes (Universitas-SrJf #),-oncotogv: Pror D; Ketut suwiv'i'. a.',.;goc61 1ri"i"".ii."l u;;;;;j, ili Dr..svahrur Rauf,.dr, spoGlx; 1i.r'nrvercias xasanuddin).Dr' T Mirza lskandar' dr' sDoGrKl ltiniversitas DiponegorJ, ii.-?.,y"a". +, spoG(K) (Univercitas Negeri sebelas Maret),siSit Purbadi' dr' spoG(K) (Universltas'lndon".i"1, so.i.r oii-.'i.i." Ina''iyrr".orogy: Dr. siti candra wind', Batiyani, ar, spoc(K)(universitas Brawirava), Baksono Winardi, dr a;5a6i7ur;;.d;;""di y."gyi1;-ir;, D..'.j*ir,""" s"ii;*. or, spoc(K)(universitas lndonesia), Dr. Benny Hasan pr.rn 
.r, E.,spocir) tu",r"i1r" irlii"i-"j.' *,'..
Editorial Assistants
Winarni. Hotnauli Junianty
Mochammad Zuhdy, Priska Dwi Wahyurini
Addres.r
Oeparurlnt'of Obstetrics & Gvnecotoqv
Faculty of Medicine Universius Airlangga - br. Soei7mo HospitalJl.HavienProfdrMoestopono.6-S,surebayaorrr,rrJiiEi" n".1,i1-irlsso r',rc, Facs:62-3 r-s03,,33
Emall: mog_obgpby@fahoo.com
Vol. 24 No. 3 September - December 2016 pISSN 0854-0381
CONTENT
1. Human pappilomavirus genotype in cervical tissue of patients with Cervical Intraepithelial Neoplasia
(CIN) 1, CIN 2, and CIN 3
Gondo Mastutik, Rahmi Alia, Alphania Rahniayu, Anny Setijo Rahaju, Renny I’tishom,
Suhartono Taat Putra ....................................................................................................................
74 – 78
2. Parity as failure determinants of labor induction in Bangka Belitung
Dina Delvin Anggriani, Lilik Herawati, Ernawati ........................................................................ 79 – 83
3. The comparison of creatinine and cystatin C value in preeclampsia severity and neonatal outcome
John Wantania, Abraham Winarto .............................................................................................. 84 – 89
4. Theurapeutic effectiveness of rat bone marrow stem cells in Poly Cystic Ovary Syndrome Mice Model
on folliculogenesis, TGF-β, GDF-9 expression, and estrogen, TNF- and androgen Levels
Budi S, Agus S, Salmon Charles S, Widjiati ................................................................................ 90 – 93
5. Influence of prenatal class to the practice of P4K (Birth Planning and Prevention of Birth Complication)
Robitha Faiza, Hari Basuki Notobroto, Bambang Trijanto, Oedojo Soedirham,
Ah. Yusuf,  Kusuma Halim .............................................................................................................
94 – 99
6. Three years survival rate of epithelial ovarian cancer patients in Dr. Kariadi Hospital,
Semarang, Central Java
Indah Nur Damayanti, Indra Yulianti, Etty Hary Kusumastuti ................................................. 100 – 104
7. Characteristics overview of mother with perinatal death at Dr. Soetomo Hospital in 2015
Yulisa Haslinda, Budi Prasetyo....................................................................................................... 105 – 108
Cover :
Cervical Intraepithelial Neoplasia (CIN) 2
with hematoxylin eosin staining (400X magnification).
This edition page 76
Mastutik et al. : Human pappilomavirus genotype in cervical tissue of patients with CIN 1, CIN 2, and CIN 3
74
Human pappilomavirus genotype in cervical tissue of patients
with Cervical Intraepithelial Neoplasia (CIN) 1, CIN 2, and CIN 3
Gondo Mastutik1, Rahmi Alia2, Alphania Rahniayu1, Anny Setijo Rahaju1, Renny I’tishom3,
Suhartono Taat Putra1
1Department of Anatomic Pathology, Faculty of Medicine, Universitas Airlangga
2Soekandar Public Regional Hospital, Mojokerto,
3Department of Medical Biology, Faculty of Medicine, Universitas Airlangga
ABSTRAK ABSTRACT
Tujuan: mengetahui genotipe HPV pada jaringan serviks
penderita lesi prekanker.
Bahan dan Metode: Penelitian observasional deskriptif dengan
pendekatan cross sectional dari blok parafin penderita CIN1,
CIN2, CIN3 di RSUD Dr Soetomo. DNA HPV diekstraksi dari
blok paraffin, kemudian dilakukan PCR dan genotiping HPV.
Sampel terdiri dari 28 blok parafin jaringan serviks penderita
CIN1, CIN2, dan CIN3. Penderita berusia antara 26-74 tahun
(standart deviasi 10,12).
Hasil: Genotipe HPV yang menginfeksi penderita CIN1 yaitu
HPV16 dan 18, CIN2 yaitu HPV16 dan 52, dan CIN3 yaitu
HPV16, 67, dan infeksi gabungan HPV16/67 dan HPV52/67.
Genotipe HPV pada infeksi tunggal terdapat 26/28 yaitu HPV16,
HPV18, HPV52, dan HPV67, dan infeksi gabungan terdapat 2/28
yaitu HPV16/67 dan HPV52/67.
Simpulan: Genotipe HPV yang paling dominan menginfeksi
penderita lesi prekanker serviks yaitu HPV16, HPV67, HPV52,
dan HPV18.
Kata kunci: lesi prekanker serviks, CIN1, CIN2, CIN3, genotipe
HPV
Objectives: to determine the genotype of HPV in patients with
precancerous lesions of cervical tissue.
Materials and Methods: An observational study with cross
sectional study of patients paraffin block CIN1, CIN2, CIN3 was
conducted in Dr Soetomo Hospital. HPV DNA was extracted
from paraffin blocks, then performed PCR and genotyping of
HPV. The sample consisted of 28 patients with cervical tissue
paraffin blocks CIN1, CIN2 and CIN3. Patients aged between 26-
74 years (standard deviation 10,12).
Results: HPV genotypes that infect patients with CIN1 were
HPV16 and 18, CIN2 were HPV16 and 52 and CIN3 were
HPV16, 67, and combined infection HPV16/67 and HPV52/67.
HPV genotypes in a single infection were 26/28 (HPV16, HPV18,
HPV52 and HPV67), and multiple infections were 2/28
(HPV16/67 and HPV52/67).
Conclusion: The most dominant HPV genotypes infect patients
with precancerous lesions of the cervix were HPV16, HPV67,
HPV52, and HPV18.
Key words: cervical precancer lession, CIN1, CIN2, CIN3, HPV
genotype
Correspondence: Gondo Mastutik, Department of Anatomic Pathology, Faculty of Medicine, Universitas Airlangga, Jl. Prof.
Dr. Moestopo 47, Surabaya 60131, Phone: 62-31-5020251 psw 182, Fax 62-31- 5026333, E-mail: gondomastutik@gmail.com
INTRODUCTION
Cervical cancer is the second most cancer of women in
the world. World Health Organization (WHO) estimates
that in Indonesia there are 13.762 Indonesian women
who are diagnosed with cervical cancer and 7.493 die
from this disease.1 The etilogy of cervical cancer is Hu-
man Pappilomavirus (HPV) infection. There are two
groups of HPV types, the high-risk HPVs, which are
associated with the development of cervical cancer,
which are HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51,
52, 53, 56, 58, 59, 61, 73 and 81, and low-risk HPVs
which are associated with the incidence of benign warts
in the oral and urogenital epithelium in adults and
children, and is rarely found in malignant tumors ie
types 6, 11, 40, 42, 43, 44, 54, 61, 72 and 81.3
Cervical cancer is preventable because they have fairly
long period of precancer. The pathological process from
HPV infection to cancer takes about 3 to 20 years.4
HPV infection causes precancerous lesion starting from
mild dysplasia or interepithelial cervical cervix (CIN) 1,
moderate dysplasia (also called CIN 2) and severe
dysplasia (also called CIN 3), laterly causes invasive
malignancy. The precancerous lesions period is a period
of silence, in which the disorder does not cause symp-
toms in patients, and therefore, regular examination
should be done to detect precancerous lesions as early
as possible. The detection of high-risk HPV type can be
used as an additional biomarkers for routine cytology
examination in precancer lesion screening, manage-
ment of abnormal border line cytology (ASCUS),
follow-up in women who have received treatment for
HSIL, and to categorize women based on precancerous
lesions and cancer risk factors.5,6 HPV genotypes exam-
ination during precancerous lesions is needed to predict
the outcome of disease in patients.
Considering those facts, the purpose of this study was to
determine the genotype of HPV in the cervical tissue of
patients with CIN 1, CIN 2 and CIN 3 and hopefuly can
be used to predict the disease outcome in patients.
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MATERIALS AND METHODS
This was an observational descriptive study with cross
sectional approach to explore the types of HPV infect-
ing patients with CIN 1, CIN 2, CIN 3, using the paraf-
fin block preparations in Dr Soetomo Hospital. The
population of this study were patients with CIN 1, CIN
2, CIN 3 who were performed histopathology examin-
ation using HE staining in the Pathology Department of
the Faculty of Medicine, Universitas Airlangga, Dr
Soetomo Hospital from January 1st to December 31st
2013. The samples were taken from cervical biopsies
procedure done towards patients with CIN 1, CIN 2 and
CIN 3, and.then processed to be paraffin blocks.
The inclusion criteria of this study were 1) histopatho-
logical examination should be performed at the
Anatomical Pathology Installation of Dr Soetomo
Hospital, 2) microscopic appearances are in accordance
with the CIN 1, CIN 2 and CIN 3 criteria, 3) tissues in
paraffin blocks are still representative for the research’
purposes. The exclusion criterias were insufficient sam-
ples and damaged tissue in the paraffin blocks.
Paraffin block numbers were firstly recorded, then the
paraffin blocks and slides which were stained by
Hematoxillin eosin (HE) were collected. The HE slides
were used for histopathological examination to deter-
mine whether or not the microscopic appearances match
the criteria in the study. Paraffin blocks which were still
representative were later used as randomy taken sam-
ples using simple random sampling technique.
HPV DNA was extracted from paraffin blocks using
Nucleospin Tissue (Macherey Nagel) reagents. The
paraffin blocks were cut using microtome, resulting 5
pieces of slides, each was 5µm thick, then tube ependrof
was inserted for deparafination process using xylol.
DNA extraction was done according to the manual
instructions for reagents usage.
Extraction product was used as a template to perform
the Polymerase Chain Reaction (PCR) technique in the
temperature of 950C for 10 minutes, 950C for 30
seconds, 500C for 30 seconds, 720C for 30 seconds in 50
cycles, and 720C for 5 minutes in 1 cycle. HPV geno-
typing is done using HPV-Type Express Ampliquality
(AB analitica) with reverse line blot technique. The
results were in the form of ribbons on a blot membrane
which is in accordance with the type of HPV. The
collected data were calculated and analyzed using
percentages and were presented in the form of images
and tables.
RESULTS AND DISCUSSION
The sample used in the study consisted of 28 paraffin
blocks of cervical tissue derived from patients with CIN
1 (10 blocks), CIN 2 (10 blocks) and CIN 3 (8 blocks).
The patients aged between 26-74 years old (standard
deviation of 10:12) (Table 1). Cervical Intraepithelial
Neoplasia (CIN) 1 was characterized by the presence of
mild dysplasia in one third layer of squamous epithelial
cells whose nucleus were about to swell and more
hyperchromatic, or the presence of cells infected with
HPV with slightly enlarged nucleus, more hyperchro-
matic, and irregular nucleus edge. The core was
surrounded by perinuclear hallo (koilositosis) (Figure
1). CIN 2 was characterized by moderate dysplasia in
two-third layer of squamous epithelial cell whose
nucleus are about to swell, and more hyperchromatic
(Figure 2). CIN 3 was characterized by severe dysplasia
in the whole layers of squamous epithelial cell whose
nucleus were enlarged, hyperchromatic, with thinner
cytoplasm (Figure 3) .10




CIN 1 29-54 8,18 10
CIN 2 26-49 7,94 10
CIN 3 41-64 7,78 8
Total of Patients 28
CIN = cervical intraepithelial neoplasia
Figure 1. Cervical Intraepithelial Neoplasia (CIN) 1 with
hematoxylin eosin staining (A 200x magnification,
and B 400X).
CIN 1, CIN 2, and CIN 3 respectively represents mild,
moderate, and severe dysplasia. Based on the
management of patients’ treatment, a new classification
system was arranged and CIN 1 was renamed into low
grade squamous intraepithelial lession (LSIL) since the
treatment of precancerous lesions is simply observation,
while CIN 2 and CIN 3 are arranged into one category
called high grade squamous intraepithelial lesion
(HSIL) since the treatment of these precancerous lesions
is done trough surgery.11,12
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Figure 2. Cervical Intraepithelial Neoplasia (CIN) 2
with hematoxylin eosin staining (400X
magnification).
Figure 3. Cervical Intraepithelial Neoplasia (CIN) 3
with hematoxylin eosin staining (A 200x
magnification, and B 400X).
HPV genotyping in this study was conducted by reverse
line blot technique that can be used to detect 40 types of
HPV, including high risk and low risk groups. HPV
types that can be detected are 6, 11, 16, 18, 26, 31, 33,
35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 58, 59,
61, 62, 64, 66, 67, 68 (AEB), 69, 70, 71, 72, 73, 81, 82,
83, 84, 87, 89, 90. The result of this HPV genotyping
test using this technique showed the ribbons that are
visible in the blot membrane (Figure 4).
Figure 4. HPV genotyping’s result with reverse line blot
technique
These results indicated that HPV genotypes that infect
patients with CIN 1, namely HPV 16 and 18, patients
with CIN 2 (HPV 16 and 52), and patients with CIN 3
(HPV 16, 67, and combined HPV 16/67 and 52/67
infection) (table 2). HPV genotypes found in patients
with single infection precancerous lesions, which was
92.9% (26/28), are HPV 16, HPV 18, HPV 52, and
HPV 67. Combining HPV genotypes, which was 7.1%
(2/28) are HPV 16/67 and 52/67 (Table 3). The most
dominant HPV genotypes in infecting patients with
cervix’ precancerous lesions in this study were HPV 16
(86%), HPV 67 (11%), HPV 52 (8%), HPV 18 (4%)
(Table 3).







CIN 1 10 HPV 16 9
HPV 18 1
CIN 2 10 HPV 16 9
HPV 52 1
CIN 3 8 HPV 16 5
HPV 67 1
HPV 16, 67 1
HPV 52, 67 1
Patients Amount 28







HPV 16 23 1 24 86
HPV 18 1 0 1 4
HPV 52 1 1 2 8
HPV 67 1 2 3 11
HPV 16/67 1 1 4
HPV 52/67 1 1 4
Total of Samples 28
CIN 1 is included to LSIL, CIN 2 and CIN 3 are includ-
ed to HSIL in Bethesda classification. All CIN1 samples
in this study are HPV positive. The prevalence of HPV
that infect HSIL patients in the world is 85% (ranging
from 78% in Asia and 85% in Europe).13 HPV geno-
types that present in LSIL cases in this research were
HPV 16 and 18, in HSIL are single infection of HPV
16, HPV 52 , HPV 67, and combined infection of HPV
16/67 and 52/67. The genotypes that infect patients with
HSIL are HPV 16, 58, 52, 18, and 51. Genotype 31,
33,35, 39, 52, 56, 58, 68, 73 are more often to be found
in HSIL than in invasive cervical carcinoma, as well as
low risk HPV such as 6, 11, 52, 66, 70, and 82 are more
frequently found in cervical carcinoma HSIL than
invasive.13
HPV genotypes found in cervical tissue of LSIL and
HSIL patients in this study were similar with the results
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of a research done in Thailand, which found that 50% of
HPV types 16 and 18 are the type that infects people in
all cases of LSIL and HSIL. HPV 16 is the most
frequent and its prevalence increases with the increasing
degree of lesion, 73.4% in LSIL, and 87.2% in HSIL. In
other hand, the prevalence of low-risk HPV types (HPV
6, 11, 40, 43, 70 and 82) is decreased or there is no
increase in the disease stage.14
HPV types that are identified in normal cervix and LSIL
in Japan are HPV-11, -16, -18, -30, -31, -33, -35, -39, -
42, -44, -45, -51, - 52, -53, -54, -55, -56, -58, -59, -61, -
62, -66, -67, -68, -72, and -73. HPV types that have
been identified on HSIL and SCC in Japan are HPV-16,
-18, -31, -33, -35, -45, -51, -52, -56, -58, and -67. In
HSIL and SCC, HPV-16 is the most infecting type,
followed by HPV-51, -52, and -58. HPV type -39, -59,
and -68 are not detected.15
This analysis showed that HPV types 16, 18, 31, 51, 52,
and 58 are often associated with the incidence of SCC,
and HPV types 16, 31, 33, 35, 45, 51, 52, 56, and 58 are
often associated with HSIL, therefore HPV-16, -18, -31,
-51, -52, -58, and possibly HPV-45 and -67 are often
considered as high risk type in Japanese women.15 HPV
types 33 and 55 are not detected as single type in
invasive cervical cancer, although they are related to
HSIL. HPV types 11, 39, 42, 44, 53, 54, 59, 61, 62, 73
are associated with the incidence of HSIL, but not
related to the HSIL and invasive cervical cancer and
therefore, these type are associated with LSIL and low
risk cancer. LSIL HPV 39, 59, and 68 are not identified
on HSIL and SCC although they are related to cancer. 15
HPV types that often infect normal cervix in Asia are
HPV 16, 52, 58, 51, 18, 56, 35, 33, 39, 31. LSIL are
HPV 16, 58, 52, 18, 51, 56, 39, 31 , 68, and 35. While
HPV 16, 58, 52, 18, 33, 51, 31, 56, 35, and 45 are
HSIL.16
HPV testing in patients with CIN2 is helpful to diagnose
borderline cases or cases of normal cytology, as well as
to follow up patients with CIN 2. HPV testing in CIN 3
are needed to monitor the cervix of patients with CIN 3
who are treated surgically. Cytological examination
during the treatment follow-up is less sensitive, since
the smear results are difficult to evaluate, while 5-10%
of patients usually experience relapse. HPV testing is
useful to follow up the those cases and is more
sensitive. Negative results imply that there is perfect
healing so that the woman can follow a routine screen-
ing .5
Detection of HPV types are generally useful to predict
the cervix of infected women. Based on the clinico-
pathology grading consensus, HPV testing can be used
to justify ASCUS clinically. Determining HPV type and
detection of multiple HPV in clinical samples can be
used as an secondary marker for cervix cell abnormal-
ities.15 High-risk types of HPV infection can trigger the
development of cervical cancer, while low-risk HPV
can lead to genital warts cases.
HPV genotypes found in LSIL cases of this research are
HPV 16 and 18. Eventhough in LSIL patients there is a
possibility of complete healing and disappearance of the
virus because of increased immunity, it is still necessary
to monitor the health of the cervix for the next 6
months. LSIL can either evolve to HSIL or recover
completely. The results of this study shows that in
LSIL, the HPV infecting cervix are the high risk types.
Therefore, it is possible to progress towards HSIL. HPV
genotypes of HSIL cases in this study are single
infections such as HPV 16, HPV 52, HPV 67, and com-
bined infections such as HPV 16/67 and 52/67. HPV
types 16, 52, and 67 are high-risk types. Combined
infection of two high-risk types of HPV can accelerate
the development towards invasive cervical carcinoma.
Patients should get conication procedure with  loop
electrical excition procedure (LEEP) to recover. HPV
testing still need to be done in patients with HSIL after
the procedure to monitor the healing progress.
High-risk HPV types are the mostly found types in
HSIL and almost all cervical cancers, while in LSIL,
obly 60% were infected with high risk HPV types.
Single or combined, high-risk HPV types infections are
more often found in HSIL and SCC compared with the
LSIL and normal cervix.15 High-risk HPV infection
infects longer than the low-risk HPV types. The
immune response in the cervix can easily beat the low-
risk HPV types, where high-risk HPV types are resistant
to immunity and infect longer. High-risk types of HPV
infection appears to be related to persistent infection and
were able to develop into HSIL and SCC.15 This study
found that the combined HPV infection is a factor in
persistent HPV infection in young women with a normal
cervix. Persistent HPV infection indicates the degree of
cervical dysplasia development. Multiple HPV infection
appears to be related to cervical neoplasia development.
Multiple infections produce conditions that alter the
immune protection to be a persistent infection.15
There are several combined infections in clinical
samples. The combined infection seems to be typical in
women with cervical abnormalities and was significant-
ly associated with the risk of LSIL, HSIL and SCC. The
combined infection is more common in LSIL compared
to malignant lesions (HSIL and SCC). 15
The results of this study indicated that the most
dominant types of HPV infecting the patients with
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cervical abnormalities in this study were HPV 16
(86%), HPV 67 (11%), HPV 52 (8%), HPV 18 (4%).
Most types of HPV that cause cervical cancer are HPV
16 and 18. The detection of high risk HPV types can be
used as an additional biomarker for routine cytologic
examina-tions in screening for precancerous lesions,
management of abnormal borderline cytology result
(ASCUS) and follow-up in women who has gone
through the treat-ments for HSIL and to categorize
women based on precancerous lesions and cancer risk
factors (Meijer CJ, et al, 2006, Youens KE, et al, 2011).
These HPV types are associated with protection against
cervical cancer. Vaccines which are available today are
HPV 16/18 bivalent and quadrivalent HPV 16/18 and
6/11 vaccine. HPV 16/18 vaccination can provide
protection against cervical cancer caused by HPV 16
and 18 infection. The second-generation of HPV
vaccines, with the addition of HPV types, is expected to
provide higher protection against progression toward
malignancy.
CONCLUSION
The most dominant HPV genotypes infecting patients
with cervical precancerous lesions in this study were
HPV 16, HPV 67, HPV 52 and HPV 18, and therefore,
HPV types 52 and 67 should be considered to be a
second-generation HPV vaccine for protection against
cervical cancer incidence in Indonesia.
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